Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains

Vaccine

Volumn 28, Issue 23, 2010, Pages 3963-3971

  Hidajat, Rachmat ^a   Kuate, Seraphin ^a   Venzon, David ^a   Kalyanaraman, Vaniambadi ^b   Kalisz, Irene ^b   Treece, James ^b   Lian, Ying ^c   Barnett, Susan W ^d   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

HIV envelope; Replication competent adenovirus; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS 1 TV1 STRAIN GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS SF162 STRAIN GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; REPLICATION COMPETENT ADENOVIRUS 5 VECTOR HOST RANGE MUTANT; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE CONSTRUCT; HOMOLOGOUS RECOMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INTERFERON PRODUCTION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS STRAIN;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C;

EID: 77952430519     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.046     Document Type: Article

References (48)

1. Hall H.I., Song R., Rhodes P., Prejean J., An Q., Lee L.M., et al. Estimation of HIV incidence in the United States. JAMA 300 5 (2008) 520-529
2. Haase A.T. The pathogenesis of sexual mucosal transmission and early stages of infection: obstacles and a narrow window of opportunity for prevention. AIDS 15 Suppl. 1 (2001) S10-S11
3. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 80 12 (2006) 6177-6181
4. Forthal D.N., Landucci G., Cole K.S., Marthas M., Becerra J.C., and Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 80 18 (2006) 9217-9225
5. Miller C.J., Genescà M., Abel K., Montefiori D., Forthal D., Bost K., et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 81 10 (2007) 5024-5035
6. Gómez-Román V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174 4 (2005) 2185-2189
7. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83 2 (2009) 791-801
8. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with tat/env compared with multigenic vaccines. J Immunol 182 6 (2009) 3718-3727
9. Malkevitch N.V., and Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 3 4 Suppl. (2004) S105-S117
10. Patterson L.J., and Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 8 9 (2008) 1347-1363
11. Wyand M.S., Manson K.H., Garcia-Moll M., Montefiori D., and Desrosiers R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 70 6 (1996) 3724-3733
12. Hofmann-Lehmann R., Vlasak J., Williams A.L., Chenine A.L., McClure H.M., Anderson D.C., et al. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17 2 (2003) 157-166
13. Klessig D.F., and Grodzicker T. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17 4 (1979) 957-966
14. Patterson L.J., Prince G.A., Richardson E., Alvord W.G., Kalyan N., and Robert-Guroff M. Insertion of HIV-1 genes into Ad4ΔE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 292 1 (2002) 107-113
15. Peng B., Wang L.R., Gómez-Román V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79 16 (2005) 10200-10209
16. Malkevitch N., Patterson L.J., Aldrich K., Richardson E., Alvord W.G., and Robert-Guroff M. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol 170 8 (2003) 4281-4289
17. Patterson L.J., Malkevitch N., Pinczewski J., Venzon D., Lou Y., Peng B., et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 77 16 (2003) 8607-8620
18. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gómez-Román V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 5 (2004) 2212-2221
19. mac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 353 1 (2006) 83-98
20. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 81 7 (2007) 3414-3427
21. 89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 374 2 (2008) 322-337
22. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382 2 (2008) 217-225
23. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185 4 (1997) 621-628
24. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73 12 (1999) 10489-10502
25. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105 21 (2008) 7552-7557
26. Natuk R.J., Chanda P.K., Lubeck M.D., Davis A.R., Wilhelm J., Hjorth R., et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci USA 89 16 (1992) 7777-7781
27. Lubeck M.D., Natuk R.J., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3 6 (1997) 651-658
28. Zhao J., Lou Y., Pinczewski J., Malkevitch N., Aldrich K., Kalyanaraman V.S., et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 21 25-26 (2003) 4022-4035
29. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71 11 (1997) 8531-8541
30. Srivastava I.K., Kan E., Sun Y., Sharma V.A., Cisto J., Burke B., et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 372 2 (2008) 273-290
31. Kothe D.L., Decker J.M., Li Y., Weng Z., Bibollet-Ruche F., Zammit K.P., et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360 1 (2007) 218-234
32. Kothe D.L., Li Y., Decker J.M., Bibollet-Ruche F., Zammit K.P., Salazar M.G., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352 2 (2006) 438-449
33. Cheng-Mayer C., Weiss C., Seto D., and Levy J.A. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci USA 86 21 (1989) 8575-8579
34. Cheng-Mayer C., Quiroga M., Tung J.W., Dina D., and Levy J.A. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 64 9 (1990) 4390-4398
35. Lian Y., Srivastava I., Gómez-Román V.R., Zur Megede J., Sun Y., Kan E., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 79 21 (2005) 13338-13349
36. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 6 3 (1996) 315-324
37. Sheay W., Nelson S., Martinez I., Chu T.H., Bhatia S., and Dornburg R. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. Biotechniques 15 5 (1993) 856-862
38. Logan J., and Shenk T. Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. Proc Natl Acad Sci USA 81 12 (1984) 3655-3659
39. Berkner K.L., and Sharp P.A. Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant. Nucleic Acids Res 13 3 (1985) 841-857
40. Kaufman R.J. Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors. Proc Natl Acad Sci USA 82 3 (1985) 689-693
41. Alonso-Caplen F.V., Katze M.G., and Krug R.M. Efficient transcription, not translation, is dependent on adenovirus tripartite leader sequences at late times of infection. J Virol 62 5 (1988) 1606-1616
42. Huang W., and Flint S.J. The tripartite leader sequence of subgroup C adenovirus major late mRNAs can increase the efficiency of mRNA export. J Virol 72 1 (1998) 225-235
43. Dolph P.J., Racaniello V., Villamarin A., Palladino F., and Schneider R.J. The adenovirus tripartite leader may eliminate the requirement for cap-binding protein complex during translation initiation. J Virol 62 6 (1988) 2059-2066
44. Dolph P.J., Huang J.T., and Schneider R.J. Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex. J Virol 64 6 (1990) 2669-2677
45. Horwitz M.S. Adenovirus immunoregulatory genes and their cellular targets. Virology 279 1 (2001) 1-8
46. Horwitz M.S. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 6 Suppl. 1 (2004) S172-S183
47. Lichtenstein D.L., Toth K., Doronin K., Tollefson A.E., and Wold W.S. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 23 1-2 (2004) 75-111
48. Le L.P., Le H.N., Nelson A.R., Matthews D.A., Yamamoto M., and Curiel D.T. Core labeling of adenovirus with EGFP. Virology 351 2 (2006) 291-302